ImmunoMark Summit London 2027: Immuno-Oncology & Biomarker Summit

The ImmunoMark Summit UK Edition returns for its second annual instalment, conceptualized and curated by Convolign Business Consulting. Building on the success of a landmark inaugural edition in 2026, the 2027 summit is larger, more ambitious, and shaped directly by the feedback of the community it serves.

As immunotherapies continue to reshape cancer care, from advanced CAR-T and TCR-T cell therapies to next-generation bispecific antibodies and AI-driven drug discovery, the identification and validation of clinically robust biomarkers has never been more central to oncology success.

Hosted in London, one of the world's foremost centres for life sciences innovation and oncology research, ImmunoMark Summit 2027 brings together pharmaceutical and biotech leaders, translational medicine experts, diagnostic developers, clinical researchers, and regulatory authorities from the UK, Europe, and beyond.

Advanced CAR-T, TCR-T and NK cell therapy innovation for solid tumours, pushing beyond the current standard of care with new modalities and combination strategies.

How artificial intelligence and machine learning are transforming biomarker identification, patient stratification, and translational acceleration at scale.

Advances in spatial biology, single-cell technologies, ctDNA and MRD detection enabling dynamic treatment monitoring and earlier clinical intervention.